Logo

Plexera Signs Early-Access Customer for ProteomicProcessor

Nov 13, 2007

NEW YORK (GenomeWeb News) - Plexera said today it has inked an agreement with an undisclosed early-access customer for its antibody discovery system, which it expects to launch in May 2008. 
 
Plexera said the partner, a therapeutic antibody company, intends to purchase one of the ProteomicProcessor Systems when the platform is commercially available.
 
The company said the system combines surface plasmon resonance technology with microarray multiplex capabilities to detect and monitor biomolecular binding kinetics for as many as 5,000 antigen-antibody interactions in one run.
 
Plexera, a subsidiary of Lumera, said its platform combines antibody screening and analysis of binding properties, concentration, and kinetics into a single process that can help speed up drug discovery research.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.